Primary refractory multiple myeloma: a real-world experience with 85 cases

Artur Jurczyszyn; Anna Waszczuk-Gajda; Jorge J. Castillo; Katarzyna Krawczyk; Martin Stork; Ludek Pour; Lidia Usnarska-Zubkiewicz; Stanisław Potoczek; Iwona Hus; Julio Davila Valls; Parameswaran Hari; Saurabh Chhabra; Massimo Gentile; Gabor Mikala; Gergely Varga; Chor Sang Chim; Mark Fiala; Ravi Vij; Natalia Schutz; Marek Rodzaj; Agnieszka Porowska; David H. Vesole; Agnieszka Druzd-Sitek; Jan Walewski; Ajay K. Nooka

doi:10.1080/10428194.2020.1788014

Primary refractory multiple myeloma: a real-world experience with 85 cases

Artur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J. Castillo, Katarzyna Krawczyk, Martin Stork, Ludek Pour, Lidia Usnarska-Zubkiewicz, Stanisław Potoczek, Iwona Hus, Julio Davila Valls, Parameswaran Hari, Saurabh Chhabra, Massimo Gentile, Gabor Mikala, Gergely Varga, Chor Sang Chim, Mark Fiala, Ravi Vij, Natalia Schutz, Marek RodzajAgnieszka Porowska, David H. Vesole, Agnieszka Druzd-Sitek, Jan Walewski, Ajay K. Nooka

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.

Original language	English
Pages (from-to)	2868-2875
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	61
Issue number	12
DOIs	https://doi.org/10.1080/10428194.2020.1788014
State	Published - Dec 2020

Keywords

Double-refractory multiple myeloma
prognosis
survival
treatment response

Access to Document

10.1080/10428194.2020.1788014

Cite this

Jurczyszyn, A., Waszczuk-Gajda, A., Castillo, J. J., Krawczyk, K., Stork, M., Pour, L., Usnarska-Zubkiewicz, L., Potoczek, S., Hus, I., Davila Valls, J., Hari, P., Chhabra, S., Gentile, M., Mikala, G., Varga, G., Chim, C. S., Fiala, M., Vij, R., Schutz, N., ... Nooka, A. K. (2020). Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 61(12), 2868-2875. https://doi.org/10.1080/10428194.2020.1788014

@article{2a2c3d825b0242d8ab34bc158d0575d3,

title = "Primary refractory multiple myeloma: a real-world experience with 85 cases",

abstract = "This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.",

keywords = "Double-refractory multiple myeloma, prognosis, survival, treatment response",

author = "Artur Jurczyszyn and Anna Waszczuk-Gajda and Castillo, {Jorge J.} and Katarzyna Krawczyk and Martin Stork and Ludek Pour and Lidia Usnarska-Zubkiewicz and Stanis{\l}aw Potoczek and Iwona Hus and {Davila Valls}, Julio and Parameswaran Hari and Saurabh Chhabra and Massimo Gentile and Gabor Mikala and Gergely Varga and Chim, {Chor Sang} and Mark Fiala and Ravi Vij and Natalia Schutz and Marek Rodzaj and Agnieszka Porowska and Vesole, {David H.} and Agnieszka Druzd-Sitek and Jan Walewski and Nooka, {Ajay K.}",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = dec,

doi = "10.1080/10428194.2020.1788014",

language = "English",

volume = "61",

pages = "2868--2875",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "12",

}

Jurczyszyn, A, Waszczuk-Gajda, A, Castillo, JJ, Krawczyk, K, Stork, M, Pour, L, Usnarska-Zubkiewicz, L, Potoczek, S, Hus, I, Davila Valls, J, Hari, P, Chhabra, S, Gentile, M, Mikala, G, Varga, G, Chim, CS, Fiala, M , Vij, R, Schutz, N, Rodzaj, M, Porowska, A, Vesole, DH, Druzd-Sitek, A, Walewski, J & Nooka, AK 2020, 'Primary refractory multiple myeloma: a real-world experience with 85 cases', Leukemia and Lymphoma, vol. 61, no. 12, pp. 2868-2875. https://doi.org/10.1080/10428194.2020.1788014

TY - JOUR

T1 - Primary refractory multiple myeloma

T2 - a real-world experience with 85 cases

AU - Jurczyszyn, Artur

AU - Waszczuk-Gajda, Anna

AU - Castillo, Jorge J.

AU - Krawczyk, Katarzyna

AU - Stork, Martin

AU - Pour, Ludek

AU - Usnarska-Zubkiewicz, Lidia

AU - Potoczek, Stanisław

AU - Hus, Iwona

AU - Davila Valls, Julio

AU - Hari, Parameswaran

AU - Chhabra, Saurabh

AU - Gentile, Massimo

AU - Mikala, Gabor

AU - Varga, Gergely

AU - Chim, Chor Sang

AU - Fiala, Mark

AU - Vij, Ravi

AU - Schutz, Natalia

AU - Rodzaj, Marek

AU - Porowska, Agnieszka

AU - Vesole, David H.

AU - Druzd-Sitek, Agnieszka

AU - Walewski, Jan

AU - Nooka, Ajay K.

PY - 2020/12

Y1 - 2020/12

N2 - This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.

AB - This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.

KW - Double-refractory multiple myeloma

KW - prognosis

KW - survival

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=85087612188&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1788014

DO - 10.1080/10428194.2020.1788014

M3 - Article

C2 - 32623944

AN - SCOPUS:85087612188

SN - 1042-8194

VL - 61

SP - 2868

EP - 2875

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

Primary refractory multiple myeloma: a real-world experience with 85 cases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this